Ironwood Pharmaceuticals Inc (IRWD) stock
Close on Nov 17, 2026Market cap $804.72MP/E 6.3Yield –
Earnings
Ironwood Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Ironwood Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | $133.00M | +8.9% | $0.36 | $0.36 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $113.04M | +32.7% | $0.31 | $0.31 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $106.50M | +159.1% | $0.24 | $0.24 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026before the open | $47.70M | -47.3% | -$0.01 | -$0.01 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | $122.10M | +33.3% | $0.23 | $0.24 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $85.20M | -9.7% | $0.14 | $0.14 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025before the open | $41.10M | -45.1% | -$0.23 | -$0.14 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | $90.50M | -23.0% | $0.02 | $0.02 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $91.60M | -19.4% | $0.02 | $0.02 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $94.40M | -12.1% | -$0.01 | $0.00 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024before the open | $74.90M | -28.0% | -$0.03 | -$0.02 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 15, 2024before the open | $117.60M | +9.7% | -$0.01 | $0.00 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | $113.70M | +4.7% | $0.09 | $0.12 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $107.40M | +10.5% | -$6.84 | -$6.71 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $104.10M | +6.8% | $0.25 | $0.25 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 16, 2023before the open | $107.20M | -8.5% | $0.27 | $0.27 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $108.60M | +4.7% | $0.28 | $0.28 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $97.20M | – | $0.21 | $0.21 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $97.50M | – | $0.21 | $0.21 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 17, 2022before the open | $117.10M | – | $0.25 | $0.27 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $103.70M | – | $0.34 | $0.33 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 11, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Ironwood Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total RevenueGAAP | FY2026 | $485.00M – $510.00M | $450.00M – $475.00M | Raised | Nov 5, 2026 |
| Total Revenue | FY2026 | $460.00M – $485.00M | $450.00M – $475.00M | Raised | Aug 6, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $350.00M | $300.00M | Raised | Nov 5, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $300.00M | $300.00M | Reaffirmed | May 7, 2026 |
| LINZESS ® U.S. net sales | FY2026 | $1.13B – $1.18B | – | New | Feb 25, 2026 |
| LINZESS® U.S. net sales | FY2026 | $1.13B – $1.18B | – | New | Jan 2, 2026 |
| U.S. LINZESS Net Sales | FY2026 | $1.20B – $1.25B | – | Raised | Nov 5, 2026 |
| U.S. LINZESS Net Sales | FY2026 | $1.15B – $1.20B | $1.13B – $1.18B | Raised | Aug 6, 2026 |
Guidance vs results
The last range Ironwood Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $290.00M – $310.00M | $296.10MΣ4Q | Within range |
Guidance history
Every forecast Ironwood Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Adjusted EBITDA | FY2026 | $350.00M | Raised |
| Nov 5, 2026 | U.S. LINZESS Net Sales | FY2026 | $1.20B – $1.25B | Raised |
| Nov 5, 2026 | Total Revenue | FY2026 | $485.00M – $510.00M | Raised |
| Aug 6, 2026 | U.S. LINZESS Net Sales | FY2026 | $1.15B – $1.20B | Raised |
| Aug 6, 2026 | Total Revenue | FY2026 | $460.00M – $485.00M | Raised |
| May 7, 2026 | Adjusted EBITDA | FY2026 | $300.00M | Reaffirmed |
| May 7, 2026 | U.S. LINZESS Net Sales | FY2026 | $1.13B – $1.18B | Reaffirmed |
| May 7, 2026 | Total Revenue | FY2026 | $450.00M – $475.00M | Reaffirmed |
| Feb 25, 2026 | adjusted EBITDA | FY2026 | $300.00M | New |
| Feb 25, 2026 | LINZESS ® U.S. net sales | FY2026 | $1.13B – $1.18B | New |
| Feb 25, 2026 | total revenues | FY2026 | $450.00M – $475.00M | New |
| Jan 2, 2026 | Adjusted EBITDA | FY2025 | $135.00M | Reaffirmed |
| Jan 2, 2026 | adjusted EBITDA | FY2026 | $300.00M | New |
| Jan 2, 2026 | LINZESS® U.S. net sales | FY2026 | $1.13B – $1.18B | New |
| Jan 2, 2026 | LINZESS U.S. net sales | FY2025 | $860.00M – $890.00M | Reaffirmed |
| Jan 2, 2026 | Total revenue | FY2025 | $290.00M – $310.00M | Reaffirmed |
| Jan 2, 2026 | total revenues | FY2026 | $450.00M – $475.00M | New |
| Nov 10, 2025 | Adjusted EBITDA | FY2025 | $135.00M | New |
| Nov 10, 2025 | U.S. LINZESS Net Sales | FY2025 | $860.00M – $890.00M | New |
| Nov 10, 2025 | Total Revenue | FY2025 | $290.00M – $310.00M | New |
| Aug 7, 2025 | Adjusted EBITDA | FY2025 | $105.00M | Reaffirmed |
| Aug 7, 2025 | U.S. LINZESS Net Sales | FY2025 | $800.00M – $850.00M | Reaffirmed |
| Aug 7, 2025 | Total Revenue | FY2025 | $260.00M – $290.00M | Reaffirmed |
| Apr 25, 2025 | adjusted EBITDA | FY2025 | $105.00M | Raised |
| Apr 25, 2025 | LINZESS U.S. net sales | FY2025 | $800.00M – $850.00M | Raised |
| Apr 25, 2025 | total Ironwood revenue | FY2025 | $260.00M – $290.00M | Lowered |
| Feb 27, 2025 | Adjusted EBITDA | FY2025 | $85.00M | New |
| Feb 27, 2025 | U.S. LINZESS Net Sales | FY2025 | $800.00M – $850.00M | New |
| Feb 27, 2025 | Total Revenue | FY2025 | $260.00M – $290.00M | New |
| Nov 7, 2024 | Adjusted EBITDA | FY2024 | $75.00M | Reaffirmed |
| Nov 7, 2024 | Total Revenue | FY2024 | $350.00M – $375.00M | Lowered |
| Nov 7, 2024 | U.S. LINZESS Net Sales | FY2024 | $900.00M – $950.00M | Raised |
| Aug 8, 2024 | Adjusted EBITDA | FY2024 | $75.00M | Lowered |
| Aug 8, 2024 | U.S. LINZESS Net Sales | FY2024 | $900.00M – $950.00M | New |
| Aug 8, 2024 | Total Revenue | FY2024 | $350.00M – $375.00M | Lowered |
| May 9, 2024 | Adjusted EBITDA | FY2024 | $120.00M | Lowered |
| May 9, 2024 | Total Revenue | FY2024 | $405.00M – $425.00M | New |
| Feb 15, 2024 | Adjusted EBITDA | FY2024 | $150.00M | New |
| Feb 15, 2024 | Total Revenue | FY2024 | $435.00M – $455.00M | New |
| Nov 9, 2023 | Adjusted EBITDA | FY2023 | -$900.00M | Reaffirmed |
| Nov 9, 2023 | U.S. LINZESS Net Sales Growth | FY2023 | +6% – +8% | Reaffirmed |
| Nov 9, 2023 | Total Revenue | FY2023 | $435.00M – $450.00M | Raised |
| Aug 8, 2023 | Adjusted EBITDA | FY2023 | -$900.00M | Lowered |
| Aug 8, 2023 | U.S. LINZESS Net Sales Growth | FY2023 | +6% – +8% | Raised |
| Aug 8, 2023 | Total Revenue | FY2023 | $435.00M – $450.00M | New |
| May 4, 2023 | Adjusted EBITDA | FY2023 | $250.00M | Reaffirmed |
| May 4, 2023 | U.S. LINZESS Net Sales Growth | FY2023 | +3% – +5% | Reaffirmed |
| May 4, 2023 | Total Revenue | FY2023 | $420.00M – $435.00M | Reaffirmed |
| Feb 16, 2023 | Adjusted EBITDA | FY2023 | $250.00M | New |
| Feb 16, 2023 | U.S. LINZESS Net Sales Growth | FY2023 | +3% – +5% | New |
| Feb 16, 2023 | Total Revenue | FY2023 | $420.00M – $435.00M | New |
| Nov 3, 2022 | Adjusted EBITDA | FY2022 | $250.00M | Reaffirmed |
| Nov 3, 2022 | Total Revenue | FY2022 | $420.00M – $430.00M | Reaffirmed |
| Aug 4, 2022 | Adjusted EBITDA | FY2022 | $250.00M | Reaffirmed |
| Aug 4, 2022 | Total Revenue | FY2022 | $420.00M – $430.00M | New |
| Feb 17, 2022 | Adjusted EBITDA | FY2022 | $250.00M | New |
| Feb 17, 2022 | Total Revenue | FY2022 | $420.00M – $430.00M | New |
| Nov 4, 2021 | Adjusted EBITDA | FY2021 | $210.00M | New |
| Nov 4, 2021 | U.S. LINZESS Net Sales Growth | FY2021 | +6% – +8% | New |
| Nov 4, 2021 | Total Revenue | FY2021 | $390.00M – $410.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Ironwood Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Update
- Results
- Results
- Results
- Results
See a number that looks wrong?